How it works:
Blocks EGFR tyrosine kinase activity to inhibit tumour cell growth
Halts progression in EGFR-mutated tumours
Used as monotherapy or in combination with chemotherapy
Recommended for:
Patients with EGFR-mutated non-small cell lung cancer
Patients with locally advanced or metastatic pancreatic cancer
For use in first-line or subsequent treatment under oncologist supervision
Non-small cell lung cancer with EGFR mutation
Locally advanced or metastatic pancreatic cancer (with gemcitabine)
Take orally at least 1 hour before or 2 hours after meals. Dosage should be prescribed by a healthcare professional. Swallow tablets whole with water without chewing.
Contraindications:
Hypersensitivity to erlotinib or excipients
Severe hepatic or renal impairment
Pregnancy and breastfeeding
Children under 18
Side Effects:
Rash, itching, dry skin
Diarrhoea, nausea
Elevated liver enzymes
Fatigue, anorexia
Interstitial lung disease (rare)
